313 related articles for article (PubMed ID: 34621854)
1. Gastric neuroendocrine neoplasms: A review.
Köseoğlu H; Duzenli T; Sezikli M
World J Clin Cases; 2021 Sep; 9(27):7973-7985. PubMed ID: 34621854
[TBL] [Abstract][Full Text] [Related]
2. [Subtype classification and clinicopathological characteristics of gastric neuroendocrine neoplasms: an analysis of 241 cases].
Zhang P; Zhang Y; Zhang C; Shi Y; Liu J; Liu Q; Yu L; Wang M; Zou G; Lou J; Chen J; Tan H
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1241-1246. PubMed ID: 27928793
[TBL] [Abstract][Full Text] [Related]
3. [Consensus and controversy on subtype classification of gastric neuroendocrine neoplasms].
Tan H
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):977-981. PubMed ID: 28900986
[TBL] [Abstract][Full Text] [Related]
4. Gastric and duodenal neuroendocrine tumours.
O'Toole D; Delle Fave G; Jensen RT
Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):719-35. PubMed ID: 23582915
[TBL] [Abstract][Full Text] [Related]
5. Histopathology of gastrointestinal neuroendocrine neoplasms.
Hirabayashi K; Zamboni G; Nishi T; Tanaka A; Kajiwara H; Nakamura N
Front Oncol; 2013; 3():2. PubMed ID: 23346552
[TBL] [Abstract][Full Text] [Related]
6. Gastric neuroendocrine neoplasms and precursor lesions: Case reports and literature review.
Boeriu A; Dobru D; Fofiu C; Brusnic O; Onişor D; Mocan S
Medicine (Baltimore); 2022 Jan; 101(2):e28550. PubMed ID: 35029217
[TBL] [Abstract][Full Text] [Related]
7. New Developments in Gastric Neuroendocrine Neoplasms.
Exarchou K; Stephens NA; Moore AR; Howes NR; Pritchard DM
Curr Oncol Rep; 2022 Jan; 24(1):77-88. PubMed ID: 35059996
[TBL] [Abstract][Full Text] [Related]
8. Novel association of duodenal gastrinoma and atrophic gastritis: case report and literature review.
Lendel I; Manni A; Ruggiero FM
Endocr Pract; 2007; 13(7):770-5. PubMed ID: 18194935
[TBL] [Abstract][Full Text] [Related]
9. The Neuroendocrine Neoplasms of the Digestive Tract: Diagnosis, Treatment and Nutrition.
Pobłocki J; Jasińska A; Syrenicz A; Andrysiak-Mamos E; Szczuko M
Nutrients; 2020 May; 12(5):. PubMed ID: 32429294
[TBL] [Abstract][Full Text] [Related]
10. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
[TBL] [Abstract][Full Text] [Related]
11. The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant.
Modlin IM; Moss SF; Gustafsson BI; Lawrence B; Schimmack S; Kidd M
Langenbecks Arch Surg; 2011 Dec; 396(8):1145-56. PubMed ID: 21523447
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
[TBL] [Abstract][Full Text] [Related]
13. Gastroenteropancreatic neuroendocrine neoplasms: A clinical snapshot.
Fernandez CJ; Agarwal M; Pottakkat B; Haroon NN; George AS; Pappachan JM
World J Gastrointest Surg; 2021 Mar; 13(3):231-255. PubMed ID: 33796213
[TBL] [Abstract][Full Text] [Related]
14. Endoscopic surveillance alone is feasible and safe in type I gastric neuroendocrine neoplasms less than 10 mm in diameter.
Exarchou K; Hu H; Stephens NA; Moore AR; Kelly M; Lamarca A; Mansoor W; Hubner R; McNamara MG; Smart H; Howes NR; Valle JW; Pritchard DM
Endocrine; 2022 Oct; 78(1):186-196. PubMed ID: 35895180
[TBL] [Abstract][Full Text] [Related]
15. Endoscopy and Endoscopic Ultrasound in Assessing and Managing Neuroendocrine Neoplasms.
O'Toole D; Palazzo L
Front Horm Res; 2015; 44():88-103. PubMed ID: 26303706
[TBL] [Abstract][Full Text] [Related]
16. Gastrointestinal neuroendocrine tumors in 2020.
Ahmed M
World J Gastrointest Oncol; 2020 Aug; 12(8):791-807. PubMed ID: 32879660
[TBL] [Abstract][Full Text] [Related]
17. Is local excision sufficient in selected grade 1 or 2 type III gastric neuroendocrine neoplasms?
Exarchou K; Kamieniarz L; Tsoli M; Victor A; Oleinikov K; Khan MS; Srirajaskanthan R; Mandair D; Grozinsky-Glasberg S; Kaltsas G; Howes N; Pritchard DM; Toumpanakis C
Endocrine; 2021 Nov; 74(2):421-429. PubMed ID: 34120313
[TBL] [Abstract][Full Text] [Related]
18. Proton Pump Inhibitor Use, Hypergastrinemia, and Gastric Carcinoids-What Is the Relationship?
McCarthy DM
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963924
[TBL] [Abstract][Full Text] [Related]
19. Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study.
Campana D; Ravizza D; Ferolla P; Faggiano A; Grimaldi F; Albertelli M; Berretti D; Castellani D; Cacciari G; Fazio N; Colao A; Ferone D; Tomassetti P
Endocrine; 2016 Jan; 51(1):131-9. PubMed ID: 25814125
[TBL] [Abstract][Full Text] [Related]
20. Management of gastric and duodenal neuroendocrine tumors.
Sato Y; Hashimoto S; Mizuno K; Takeuchi M; Terai S
World J Gastroenterol; 2016 Aug; 22(30):6817-28. PubMed ID: 27570419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
